T. Rowe Price Associates
ORMP icon

T. Rowe Price Associates’s Oramed Pharmaceuticals ORMP Stock Holding History

T. Rowe Price Associates’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Buy
+27,909
New +$111K ﹤0.01% 3101

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's ORMP Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 27,909 shares worth $135K. The stake represents ﹤0.01% of the portfolio and ranks #3101 among its holdings.

84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • T. Rowe Price Associates held 27,909 shares of Oramed Pharmaceuticals worth $135K as of Q2 2026.
  • Oramed Pharmaceuticals was a new T. Rowe Price Associates position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3101 holding.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.